Antidepressant treatment in anxiety disorders

Current Topics in Behavioral Neurosciences

Volumn 2, Issue , 2010, Pages 361-390

  Bespalov, Anton Y ^a   van Gaalen, Marcel M ^a   Gross, Gerhard ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Antidepressant drugs; Anxiety; Preclinical models; SSRI

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ANXIOLYTIC AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BRAIN REGION; COGNITION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXPLORATORY BEHAVIOR; GENERALIZED ANXIETY DISORDER; HIPPOCAMPUS; HUMAN; NEUROANATOMY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SOCIAL BEHAVIOR; SOCIAL PHOBIA; SOCIAL STRESS; TRANQUILIZING ACTIVITY; VOCALIZATION; ANIMAL; DRUG EFFECT; PHOBIA; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PHOBIC DISORDERS; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 79952258678     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2009_3     Document Type: Review

References (103)

1. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM (2004) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642-1649
2. Allgulander C, Florea I, Trap Huusom AK (2005) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:1-11
3. Allsopp LF, Cooper GL, Poole PH (1984) Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 9:64-70
4. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF (2005) Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 8:365-371
5. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312
6. Barrett JE, Gleeson S (1991) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: drug discrimination studies. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines, their comparative behavioural pharmacology. Wiley, Chichester, pp 59-105
7. Beck AT (2008) The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry 165:969-977
8. Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125:141-149
9. Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-151
10. Bill DJ, Knight M, Forster EA, Fletcher A (1991) Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br J Pharmacol 103:1857-1864
11. Bishop SJ (2009) Trait anxiety and impoverished prefrontal control of attention. Nat Neurosci 12:92-98
12. Blanchard DC, Griebel G, Blanchard RJ (2003) The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463:97-116
13. Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62(Suppl 15):12-17
14. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163:121-141
15. Bruijnzeel AW, Stam R, Compaan JC, Croiset G, Akkermans LM, Olivier B, Wiegant VM (1999) Long-term sensitization of Fos-responsivity in the rat central nervous system after a single stressful experience. Brain Res 819:15-22
16. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
17. Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T (2004) Anxiolytic-and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 485:145-158
18. Cook P, Wallace M, Singer G (1983) A reinterpretation of schedule-induced behaviors based on a systematic analysis of behavior. Neurosci Biobehav Rev 7:97-104
19. Coric V, Goddard A, Oren D, Pultz J, Dockens R, Wu X, Gentile K, Thomas M, D'Souza B, Shekhar A, Stock E (2008) A randomized, double-blind, placebo-controlled and active comparator trial of pexacerfont, a corticotropin releasing factor receptor-1 antagonist, in the treatment of generalized anxiety disorder. Paper presented at 47th ACNP meeting, Scottsdale, Arizona, 7-11 December, 2008
20. Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T (2005) Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 111:429-435
21. Davidson JR, Bose A, Korotzer A, Zheng H (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240
22. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212-220
23. Den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59-74
24. Dobrossy MD, Drapeau E, Aurousseau C, Le Moal M, Piazza PV, Abrous DN (2003) Differential effects of learning on neurogenesis: learning increases or decreases the number of newly born cells depending on their birth date. Mol Psychiatry 8:974-982
25. Drew MR, Hen R (2007) Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Targets 6:205-218
26. Falk JL (1971) The nature and determinants of adjunctive behavior. Physiol Behav 6:577-588
27. File SE, Ouagazzal AM, Gonzalez LE, Overstreet DH (1999) Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function. Pharmacol Biochem Behav 62:695-701
28. Fineberg NA, Drummond LM (1995) Anxiety disorders: drug treatment of behavioral cognitive psychotherapy? CNS Drugs 3:448-466
29. Foa EB, Davidson JRT, Frances A (1999) The expert consensus guidelines series: treatment of posttraumatic stress disorder. J Clin Psychiatry 60(Suppl 16):1-76
30. Fricchione G (2004) Generalized anxiety disorder. N Engl J Med 351:675-682
31. Garner JP, Weisker SM, Dufour B, Mench JA (2004) Barbering (fur and whisker trimming) by laboratory mice as a model of human trichotillomania and obsessive-compulsive spectrum disorders. Comp Med 54:216-224
32. Goodwin GM (1989) The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuropsychopharmacol Biol Psychiatry 13:445-451
33. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395
34. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57-66
35. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167-174
36. Hashimoto S, Inoue T, Muraki I, Koyama T (2009) Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog Neuropsychopharmacol Biol Psychiatry 33:113-117
37. Hettema JM (2008) What is the genetic relationship between anxiety and depression? Am J Med Genet Part C Semin Med Genet 148C:140-147
38. Hodgson RA, Guthrie DH, Varty GB (2008) Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs. Pharmacol Biochem Behav 88:341-348
39. Hoffman EJ, Mathew SJ (2008) Anxiety disorders: a comprehensive review of pharmacotherapies. Mount Sinai J Med 75:248-262
40. Hogg S, Dalvi A (2004) Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT(1A) and 5-HT(1B) receptor antagonists. Pharmacol Biochem Behav 77:69-75
41. Hogg S, Michan L, Jessa M(2006) Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. Neuropharmacology 51:141-145
42. Inoue T, Nakagawa S, Izumi T, Kitaichi Y, Koyama T (2006) Effect of combined treatment with noradrenaline and serotonin reuptake inhibitors on conditioned freezing. Eur J Pharmacol 540:91-95
43. Ising M, Zimmermann US, Künzel HE, Uhr M, Foster AC, Learned-Coughlin SM, Holsboer F, Grigoriadis DE (2007) High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32:1941-1949
44. Joel D (2006) Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 30:374-388
45. Jones N, King SM, Duxon MS (2002) Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide. Behav Pharmacol 13:525-535
46. Kahn RJ, McNair DM, Frankenthaler LM (1987) Tricyclic treatment of generalized anxiety disorder. J Affect Disord 13:145-151
47. Katon WJ (2006) Panic disorder. N Engl J Med 354:2360-2367
48. Keeney AJ, Hogg S (1999) Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression. Behav Pharmacol 10:753-764
49. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
50. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49:281-285
51. Lissek S, Levenson J, Biggs AL, Johnson LL, Ameli R, Pine DS, Grillon C (2008) Elevated fear conditioning to socially relevant unconditioned stimuli in social anxiety disorder. Am J Psychiatry 165:124-132
52. Liston C, McEwen BS, Casey BJ (2009) Psychosocial stress reversibly disrupts prefrontal processing and attentional control. Proc Natl Acad Sci USA 106:912-917
53. Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, Morrison JH, McEwen BS (2006) Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci 26:7870-7874
54. Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O'Neil PM, Ballenger JC (1993) Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29:183-188
55. Malatynska E, Rapp R, Harrawood D, Tunnicliff G (2005) Submissive behavior in mice as a test for antidepressant drug activity. Pharmacol Biochem Behav 82:306-313
56. Manfro GG, Otto MW, McArdle ET, Worthington JJ III, Rosenbaum JF, Pollack MH (1996) Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord 41:135-139
57. Marshall RD, Beebe KL, Oldham M, Zaninelli R (2001) Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 158:1982-1988
58. McNaughton N, Kocsis B, Hajos M (2007) Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function? Behav Pharmacol 18:329-346
59. Mitchell PJ (2005) Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526:147-162
60. Mongeau R, de Montigny C, Blier P (1994) Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10:41-51
61. Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP (2005) A 24-week randomized, doubleblind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278
62. Nagatani T, Yamamoto T, Sugihara T, Ueki S (1987) The effect of agonists at the GABAbenzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test. Eur J Pharmacol 142:17-22
63. Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, Kudoh A, Tada K, Yoshioka K, Kawamoto M, Togao O, Kanba S (2005) Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 57:901-910
64. Nevin JA, Grace RC, Holland S, McLean AP (2001) Variable-ratio versus variable-interval schedules: Response rate, resistance to change, and preference. J Exp Anal Behav 76:43-74
65. Nutt DJ, Bell CJ, Malizia AL (1998) Brain mechanisms of social anxiety disorder. J Clin Psychiatry 59(Suppl 17):4-11
66. Olié JP, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673
67. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B (2007) A double-blind study of the efficacy of venlafaxine extendedrelease, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24:1-14
68. Pollak DD, Monje FJ, Zuckerman L, Denny CA, Drew MR, Kandel ER (2008) An animal model of a behavioral intervention for depression. Neuron 60:149-161
69. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
70. Rickels K, DeMartinis N, Garcia-Espana F (2000) Imipramine and buspirone in treatment of patients with generalized anxiety disorder for discontinuing long-term benzodiazepine therapy. Am J Psychiatry 157:1973-1979
71. Rickels K, Downing R, Schweizer E, Hassman H (1993) Antidepressants for the treatment of generalized anxiety disorder: a placebo controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884-895
72. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749-756
73. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE (2007) Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113:134-153
74. Rupp H, Maisch B, Brilla CG (1997) Schedule-induced psychological stress and molecular structures of cardiomyocytes. Am J Physiol 272:R776-R782
75. Schneier FR (2006) Social anxiety disorder. N Engl J Med 355:1029-1036
76. Schruers K, Koning K, Luermans J, Haack MJ, Griez E (2005) Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261-271
77. Sheehan DV, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37:51-59
78. Sherman AD, Sacquitne JL, Petty F (1982) Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 16:449-454
79. Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallon BA, Davies S, Klein DF, Liebowitz MR (1998) Imipramine in the treatment of social phobia. J Clin Psychopharmacol 18:132-135
80. Soderpalm B, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol Biochem Behav 32:259-265
81. Sokolowski JD, Seiden LS (1999) The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology 147:153-161
82. Stam R (2007) PTSD and stress sensitisation: A tale of brain and body. Part 2: animal models. Neurosci Biobehav Rev 31:558-584
83. Steckler T (2009) Developing small molecule non-peptidergic drugs for the treatment of anxiety disorders-is the challenge still ahead? Curr Top Behav Neurosci. doi:10.1007/7854_2009_14
84. Stein DJ, Ahokas AA, de Bodinat C (2008) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:561-566
85. Stein DJ, Ipser JC, Balkom AJ (2004) Pharmacotherapy for social phobia. Cochrane Database Syst Rev 4:CD001206
86. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 177:280-288
87. Stein MB, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115-1125
88. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 14:2579-2584
89. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258
90. Szabo ST, Blier P (2001) Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse 42:203-212
91. Szabo ST, de Montigny C, Blier P (1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 126:568-571
92. Thiebot MH, Soubrie P, Simon P (1985) Is delay of reward mediated by shock-avoidance behavior a critical target for anti-punishment effects of diazepam in rats? Psychopharmacology (Berl) 87:473-479
93. Tsetsenis T, Ma XH, Lo IL, Beck SG, Gross C (2007) Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nat Neurosci 10:896-902
94. Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999a) Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur Neuropsychopharmacol 9(Suppl 6):393-398
95. Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999b) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J Clin Psychopharmacol 19(Suppl 2):23-29
96. van Dijken HH, Tilders FJH, Olivier B, Mos J (1992) Effect of anxiolytic and antidepressant drugs on long-lasting behavioural deficits resulting from one short stress experience in male rats. Psychopharmacology 109:395-402
97. Van Gaalen MM (2001) Long-term alterations in the corticotrophin-releasing hormone system: effects on emotional function and attention. PhD thesis, Max Planck Institute of Psychiatry, Munich, Germany
98. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31-37
99. Versiani M, Mundim FD, Nardi AE, Liebowitz MR (1988) Tranylcypromine in social phobia. J Clin Psychopharmacol 8:279-283
100. Wettstein JP (1992) 5-HT3 receptor ligands as potential anxiolytics. In: HamonM(ed) Central and peripheral 5-HT3 receptors. Academic, London, pp 257-274
101. Wieland S, Lucki I (1990) Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101:497-504
102. Wolff MC, Leander JD (2002) Selective serotonin reuptake inhibitors decrease impulsive behavior as measured by an adjusting delay procedure in the pigeon. Neuropsychopharmacology 27:421-429
103. Zhang Y, Raap DK, Garcia F, Serres F, Ma Q, Battaglia G, Van de Kar LD (2000) Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res 855:58-66